Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polyethylene Glycol Loxenatide vs Gliclazide on Brain Function in T2DM
NCT06217887Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- May 2020
- Primary completion
- Feb 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Change of olfactory brain activation by fMRI at 4 months. Started May 2020; status: recruiting.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06217887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217887.